Преглед према Пројекат
F. Hoffmann-La Roche Ltd.Hoffmann-La Roche
Приказ резултата 1 до 5 од 5
| Година | Наслов | Аутор(и) | Тип резултата | Мп-кат. |
| 2021 | Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C | Dziadziuszko, R; ...; Andric, Zoran G   ; ...; (broj, koautora 20) | Конференцијски рад | |
| 2020 | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 21) | Конференцијски рад | |
| 2021 | Original Research Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study | O'Shaughnessy, Joyce; ...; Cvetanovic, Ana S; ...; Stamatovic, Ljiljana | Научни чланак | 21aM21a - Водећи међународни часопис категорије M21a |
| 2020 | Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study | O'Shaughnessy, Joyce; ...; Cvetanovic, Ana; ...; Stamatovic, Ljiljana | Конференцијски рад | |
| 2021 | Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC | Jassem, Jacek; ...; Andric, Zoran G ; ...; (broj, koautora 19) | Научни чланак | 21a+M21a+ - Водећи међународни часопис категорије M21a+ |